Al- Anbar Medical Journal

Application of 40% Trichloroacetic Acid in the Treatment for Recurrent Genital Herpes

Document Type : Original articles

Author

Department of Dermatology, Al-Husein Teaching Hospital, Muthanna Health Directorate, Muthanna, Iraq

Abstract

Background: Genital herpes is one of the common sexually transmitted diseases affect more than 400,000,000 individuals worldwide. The disease characterized by relapse and remission courses and caused by herpes simplex virus (HSV) type 2. However, satisfactory curative agents are still unavailable.
Objectives: This study intends to evaluate the benefit of 40% Trichloroacetic acid (TCA) in the management of recurrent genital herpes lesions of the external male genitalia and to detect the recurrence rate during this therapeutic regimen.
Materials and Methods: The study extended between 1998 to 2017 and totally, 175 patients with active disease were treated by oral administration of acyclovir 400mg 5 times per day for 5 days. Only 99 patients were followed up for one year and enrolled in the study. After 2 weeks, the recurrent cases were subjected to the chemicals peeling using topical application of 40% TCA at the site of reactivation.
Results: The most affected age group was 40-50 years (n=45, 45.45%). The neck of the penis was the most affected site (n=56, 56.57%). Forty patients had only one recurrence during a one-year follow-up after treatment with 40% TCA.  
Conclusion: This study approved the clinical effectiveness of the topical application of 40 % TCA in reducing the recurrence rate of the genital herpes lesions. We recommend using this chemical peeling method in the treatment of patients with genital herpes.

Keywords

Main Subjects

References
[1]      J. Romaní, “Dermatology, Jean L. Bolognia, Joseph L. Jorizzo, Julie V. Schaffer. 2012. Editorial Saunders, Reino Unido. ISBN-13: 9780723435716; 2.494 páginas.” Elsevier Doyma, 2012.
[2]      F. Xu et al., “Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States,” Jama, vol. 296, no. 8, pp. 964–973, 2006.
[3]      O. Kortekangas-Savolainen, E. Orhanen, T. Puodinketo, and T. Vuorinen, “Epidemiology of genital herpes simplex virus type 1 and 2 infections in southwestern Finland during a 10-year period (2003–2012),” Sex. Transm. Dis., vol. 41, no. 4, pp. 268–271, 2014.
[4]      R. Gupta, T. Warren, and A. Wald, “Genital herpes,” Lancet, vol. 370, no. 9605, pp. 2127–2137, 2007.
[5]      A. Wald, M. Ericsson, E. Krantz, S. Selke, and L. Corey, “Oral shedding of herpes simplex virus type 2,” Sex. Transm. Infect., vol. 80, no. 4, pp. 272–276, 2004.
[6]      K. E. Mark et al., “Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults,” J. Infect. Dis., vol. 198, no. 8, pp. 1141–1149, 2008.
[7]      D. T. Fleming et al., “Herpes simplex virus type 2 in the United States, 1976 to 1994,” N. Engl. J. Med., vol. 337, no. 16, pp. 1105–1111, 1997.
[8]      L. Corey, H. G. Adams, Z. A. Brown, and K. K. Holmes, “Genital herpes simplex virus infections: clinical manifestations, course, and complications,” Ann. Intern. Med., vol. 98, no. 6, pp. 958–972, 1983.
[9]      D. W. Kimberlin and D. J. Rouse, “Genital herpes,” N. Engl. J. Med., vol. 350, no. 19, pp. 1970–1977, 2004.
[10]    A. Birkmann and H. Zimmermann, “HSV antivirals–current and future treatment options,” Curr. Opin. Virol., vol. 18, pp. 9–13, 2016.
[11]    D. Baker and D. Eisen, “Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies,” Cutis, vol. 71, no. 3, pp. 239–242, 2003.
[12]    J. F. Rooney et al., “Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial,” Ann. Intern. Med., vol. 118, no. 4, pp. 268–272, 1993.
[13]    G. Gabriel and R. N. Thin, “Treatment of anogenital warts. Comparison of trichloracetic acid and podophyllin versus podophyllin alone.,” Sex. Transm. Infect., vol. 59, no. 2, pp. 124–126, 1983.
[14]    A. N. Abdullah, M. Walzman, and A. Wade, “Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid.,” Sex. Transm. Dis., vol. 20, no. 6, pp. 344–345, 1993.
[15]    D. B. Schwartz, M. D. Greenberg, Y. Daoud, and R. Reid, “Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy,” Am. J. Obstet. Gynecol., vol. 158, no. 6, pp. 1407–1416, 1988.
[16]    M. J. Godley, C. S. Bradbeer, M. Gellan, and R. N. Thin, “Cryotherapy compared with trichloroacetic acid in treating genital warts.,” Sex. Transm. Infect., vol. 63, no. 6, pp. 390–392, 1987.
[17]    R. Romero and I. Nygaard, “CDC updates guidelines for treating sexually transmitted diseases,” Am. J. Obstet. Gynecol., vol. 213, no. 2, p. 117, 2015.
[18]    W. H. Organization, WHO guidelines for the treatment of genital herpes simplex virus. World Health Organization, 2016.
[19]    S. R. Knox, L. Corey, H. A. Blough, and A. M. Lerner, “Historical findings in subjects from a high socioeconomic group who have genital infections with herpes simplex virus.,” Sex. Transm. Dis., vol. 9, no. 1, pp. 15–20, 1982.
Al- Anbar Medical Journal
Volume 16, Issue 1
June 2020
Page 17-20
Files
Share
Export Citation
Statistics